Ms. Jane Wasman, J.D., is President International, General Counsel, Corporationrationrate Secretary of Acorda Therapeutics, Inc. She was appointed as President International of the Company on October 9, 2012. She served as Chief Strategic Development of the Company. From May 2004 until January 2012, she was the company Executive Vice President, General Counsel and Corporationrationrate Secretary. From 1995 to 2004, Ms. Wasman held various leadership positions at ScheringPlough Corporationrationration, including Staff Vice President and Associate General Counsel responsible for legal support for U.S. Pharmaceuticals operations, including sales, marketing and compliance; FDA regulatory matters; global research and development; and corporate licensing and business development. She served as Staff Vice President, International in 2001 and as Staff Vice President, European OperationsLegal from 1998 to 2000. Previously, Ms. Wasman specialized in litigation at Fried, Frank, Harris, Shriver & Jacobson. She also served as Associate General Counsel to the U.S. Senate Committee on Veteran?s Affairs. Ms. Wasman graduated Magna Cum Laude and Phi Beta Kappa from Princeton University and earned her J.D. from Harvard Law School
Chief - Strategic Development, General Counsel, Corporate Secretary
Age: 53 Executive Since 2012
|Wasman is a member of the board of directors and the executive committee of the board of the New York Biotechnology Association .|
The company has return on total asset (ROA) of 1.96 % which means that it generated profit of $1.96 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 47.8 % meaning that it created $47.8 on every $100 dollars invested by stockholders.
The company currently holds 1.14 M in liabilities. Acorda Therapeutics Inc has Current Ratio of 4.0 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
Entity SummaryAcorda Therapeutics, Inc., a commercialstage biopharmaceutical company, engages in the identification, development, and commercialization of therapies for multiple sclerosis , spinal cord injury , and other central nervous system disorders primarily in the United States. Acorda Therapeutics Inc [ACOR] is traded on NASDAQ in USA. It is located in Acorda Therapeutics, Inc.Ardsley, NY and employs 378 people. Filter other
|Click to run this filter|| |
Filter Other Insiders
| ACOR Nasdaq
Acorda Therapeutics Inc
Currency: USD - US Dollar
Traded on NASDAQ
Acorda Therapeutics Inc has less than 1.0 (%) percent chance of experiencing financial distress in the next 2 years of operations.
Acorda price boundaries
Promote Acorda and Jane Wasman